Axsome Therapeutics (NASDAQ:AXSM) Earns “Equal Weight” Rating from Morgan Stanley

Axsome Therapeutics (NASDAQ:AXSM)‘s stock had its “equal weight” rating restated by Morgan Stanley in a research note issued on Thursday,Benzinga reports. They presently have a $204.00 price objective on the stock, up from their previous price objective of $196.00. Morgan Stanley’s target price suggests a potential upside of 19.51% from the stock’s current price.

Other equities research analysts have also issued reports about the stock. Oppenheimer reissued an “outperform” rating and set a $220.00 target price on shares of Axsome Therapeutics in a research note on Wednesday, December 31st. HC Wainwright upped their price target on Axsome Therapeutics from $185.00 to $200.00 and gave the stock a “buy” rating in a report on Monday. Mizuho set a $217.00 price target on Axsome Therapeutics in a research report on Wednesday, December 31st. Wells Fargo & Company dropped their price objective on Axsome Therapeutics from $163.00 to $157.00 and set an “overweight” rating on the stock in a report on Tuesday, November 4th. Finally, B. Riley assumed coverage on Axsome Therapeutics in a research note on Wednesday, October 1st. They set a “buy” rating and a $179.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Axsome Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $192.35.

Axsome Therapeutics Trading Down 0.7%

NASDAQ AXSM opened at $170.69 on Thursday. Axsome Therapeutics has a 12-month low of $79.19 and a 12-month high of $184.40. The company has a fifty day simple moving average of $149.54 and a two-hundred day simple moving average of $127.07. The company has a current ratio of 1.57, a quick ratio of 1.50 and a debt-to-equity ratio of 1.66. The stock has a market cap of $8.60 billion, a P/E ratio of -36.55, a P/E/G ratio of 9.06 and a beta of 0.44.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). The company had revenue of $170.99 million for the quarter, compared to analysts’ expectations of $162.96 million. Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. Axsome Therapeutics’s revenue was up 63.2% compared to the same quarter last year. On average, analysts forecast that Axsome Therapeutics will post -2.79 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Mark E. Saad sold 37,577 shares of the stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $165.18, for a total value of $6,206,968.86. Following the completion of the transaction, the director directly owned 10,002 shares of the company’s stock, valued at approximately $1,652,130.36. This represents a 78.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Herriot Tabuteau sold 91,705 shares of the firm’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $132.34, for a total value of $12,136,239.70. Following the completion of the transaction, the chief executive officer owned 7,229 shares in the company, valued at $956,685.86. The trade was a 92.69% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 420,903 shares of company stock valued at $63,552,838 in the last three months. Insiders own 22.30% of the company’s stock.

Hedge Funds Weigh In On Axsome Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of AXSM. Vanguard Group Inc. grew its stake in Axsome Therapeutics by 6.0% during the 3rd quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company’s stock valued at $507,739,000 after acquiring an additional 235,626 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Axsome Therapeutics by 84.1% during the 3rd quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock worth $162,082,000 after purchasing an additional 609,516 shares during the last quarter. Invesco Ltd. grew its position in shares of Axsome Therapeutics by 73.3% in the third quarter. Invesco Ltd. now owns 990,557 shares of the company’s stock valued at $120,303,000 after purchasing an additional 419,008 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Axsome Therapeutics by 5.8% in the second quarter. Geode Capital Management LLC now owns 989,453 shares of the company’s stock valued at $103,303,000 after purchasing an additional 54,600 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of Axsome Therapeutics by 5.8% in the second quarter. State Street Corp now owns 958,503 shares of the company’s stock valued at $100,058,000 after purchasing an additional 52,483 shares during the last quarter. 81.49% of the stock is owned by hedge funds and other institutional investors.

More Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: HC Wainwright raised 2026 earnings estimates substantially (Q2, Q3, Q4 and FY2026 to $3.72 EPS total) and reiterated a “Buy” rating with a $200 price target — this signals higher expected profitability and gives investors a near-term target above current levels.
• Positive Sentiment: UBS reiterated its Buy rating on AXSM, reinforcing institutional analyst support that can buoy demand for the shares. UBS Sticks to Their Buy Rating for Axsome Therapeutics
• Positive Sentiment: Market commentary highlights two late-2025 FDA developments — acceptance of a supplemental filing for AXS-05 (agitation in Alzheimer’s) and FDA support for an NDA filing for AXS-12 (narcolepsy). Those regulatory moves expand potential indications and revenue runway, and underpin the bullish analyst view. Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out
• Neutral Sentiment: Street positioning remains overwhelmingly positive (majority of analysts are Buy) and recent reiterations/price targets suggest upside, but consensus still reflects variability in timing and magnitude of revenue from new indications.
• Negative Sentiment: CEO insider sales — Herriot Tabuteau sold a combined 139,414 shares across Jan. 5–7 for roughly $23.88M in proceeds; after these trades the CEO directly owns 7,229 shares (a ~90%+ reduction in their position). Large, concentrated insider selling can create near‑term selling pressure and raise governance/optics concerns for some investors. SEC Filing — Insider Transactions

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.